• Go to navigation
  • Go to content
Welcome to Zomig.info!

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca
  • Zomig
  • Zomig Rapimelt
  • Zomig Nasal Spray

Main navigation

  • Home
  • Is it Migraine?
  • Learn About Migraine
    • Migraine Aetiology
    • Migraine Epidemiology
      • Economic Impact of Migraine
  • Treating Migraine
  • Help For Your Migraine Patients
  • Scientific Opinions
  • Learn about Zomig
  • eDetailing
  • Prescribing Information
  • Migraine Glossary and Useful Links
  • References
  • About AstraZeneca
  • Sitemap

You are here

  • Home
  • Learn About Migraine
  • Migraine Epidemiology
  • Economic Impact of Migraine

Although heterogeneous in nature, migraine is a markedly disabling condition for a large proportion of sufferers. As such, migraine imposes a huge economic burden on society from lost work time and reduced productivity, amounting to several tens of millions of dollars every year.

  • Data from the USA show that migraineurs require between 3.8 (men) and 5.6 (women) days of bed rest a year, resulting in 112 million bed-ridden days per annum. This is estimated to cost US employers close to $8 billion due to missed workdays. [44]
  • Patients with migraine self-report that they are only 46% effective when working with symptoms of migraine. Each year, migraineurs lose 8.3 days due to absenteeism and 11.2 days due to reduced work days, resulting in an estimated annual cost to employers of US$ 3309 per patient. [45]
  • The total healthcare costs of a family with a migraineur are 70% higher than those of a family without a migraineur. [46]

Back to top

Not signed in



  • Register
  • Forgotten password?

Page tools

  • Print
  • Bookmark this page

Clinical Product Summary

  • Zomig Nasal Spray
  • Zomig Rapimelt

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2008